Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 2:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 49 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Candidiasis, Oral Clear all
Completed Not applicable Interventional

A Comparison of the Safety and Effectiveness of Fluconazole or Clotrimazole in the Treatment of Fungal Infections of the Mouth and Throat in Patients With AIDS

NCT00002282
View directory record Official record
Conditions
Candidiasis, Oral, HIV Infections
Interventions
Clotrimazole, Fluconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
17
States / cities
Los Angeles, California • Oakland, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 12, 2026, 2:54 PM EDT
Completed Phase 2 Interventional Results available

Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To 11 Years Old Who Are At High Risk For Systemic Fungal Infection

NCT00739934
View directory record Official record
Conditions
Candidiasis, Candidemia
Interventions
voriconazole (Vfend)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years to 11 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
14
States / cities
Tucson, Arizona • Orange, California • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2011 · Synced Sep 12, 2026, 2:54 PM EDT
Completed Phase 2 Interventional

A Study of Amphotericin B in the Treatment of Fungal Infections of the Mouth in HIV-Infected Patients Who Have Not Had Success With Fluconazole

NCT00001065
View directory record Official record
Conditions
Candidiasis, Oral, HIV Infections
Interventions
Amphotericin B
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
30
States / cities
Birmingham, Alabama • Los Angeles, California • San Jose, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 12, 2026, 2:54 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis

NCT03987620
View directory record Official record
Conditions
Candida Vulvovaginitis
Interventions
Ibrexafungerp, Placebo
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
12 Years and older · Female only
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
21
States / cities
Mesa, Arizona • Lakewood, Colorado • New Haven, Connecticut + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2021 · Synced Sep 12, 2026, 2:54 PM EDT
Recruiting Phase 3 Interventional

A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.

NCT05421858
View directory record Official record
Conditions
Candidemia, Candidiasis, Invasive
Interventions
Fosmanogepix, Caspofungin, Fluconazole, Placebo
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
23
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 12, 2026, 2:54 PM EDT
Completed Phase 3 Interventional

A Study of Fluconazole in the Treatment of Fungal Infections of the Throat in Patients With Weakened Immune Systems

NCT00002339
View directory record Official record
Conditions
Candidiasis, Esophageal, HIV Infections
Interventions
Fluconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Los Angeles, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 12, 2026, 2:54 PM EDT
Completed Not applicable Interventional

The Safety and Effectiveness of Peridex in Preventing or Delaying Fungal Infections of the Mouth in HIV-Infected Patients

NCT00002431
View directory record Official record
Conditions
Candidiasis, Oral, HIV Infections
Interventions
Chlorhexidine gluconate
Drug
Lead sponsor
Procter and Gamble
Industry
Eligibility
13 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
Los Angeles, California • San Francisco, California • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 12, 2026, 2:54 PM EDT
Terminated Phase 3 Interventional Results available

A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole

NCT05178862
View directory record Official record
Conditions
Candidiasis, Invasive, Candidemia
Interventions
SCY-078, Fluconazole, Echinocandin
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
26
States / cities
Birmingham, Alabama • Tucson, Arizona • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 12, 2026, 2:54 PM EDT
Completed Phase 4 Interventional

Fluconazole Prophylaxis of Thrush in AIDS

NCT00001542
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, Candidiasis, Oral Candidiasis
Interventions
fluconazole
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 12, 2026, 2:54 PM EDT
Completed Phase 4 Interventional Results available

Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis

NCT00496197
View directory record Official record
Conditions
Candidiasis
Interventions
Eraxis (anidulafungin), Diflucan (fluconazole), Vfend (voriconazole)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
39
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2011 · Synced Sep 12, 2026, 2:54 PM EDT
Completed Not applicable Interventional

A Study of Nystatin in the Prevention of Fungal Infections of the Mouth in Patients With AIDS or AIDS-Related Syndromes

NCT00002293
View directory record Official record
Conditions
Candidiasis, Oral, HIV Infections
Interventions
Nystatin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Birmingham, Alabama • Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 1, 2007 · Synced Sep 12, 2026, 2:54 PM EDT
Completed Not applicable Interventional

Randomized, Controlled, Double-Blind Study of Itraconazole Oral Solution Versus Fluconazole Tablets for the Treatment of Esophageal Candidiasis.

NCT00002132
View directory record Official record
Conditions
Candidiasis, Esophageal, HIV Infections
Interventions
Itraconazole, Fluconazole
Drug
Lead sponsor
Janssen Pharmaceuticals
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
18
States / cities
Tucson, Arizona • Los Angeles, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 12, 2026, 2:54 PM EDT
Completed Phase 3 Interventional Results available

A Study of Oral Oteseconazole for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)

NCT03562156
View directory record Official record
Conditions
Recurrent Vulvovaginal Candidiasis
Interventions
Oteseconazole (VT-1161), Placebo
Drug
Lead sponsor
Mycovia Pharmaceuticals Inc.
Industry
Eligibility
12 Years and older · Female only
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
25
States / cities
Birmingham, Alabama • San Diego, California • Lauderdale Lakes, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 12, 2026, 2:54 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)

NCT02267382
View directory record Official record
Conditions
Recurrent Vulvovaginal Candidiasis
Interventions
VT-1161, Placebo
Drug
Lead sponsor
Viamet
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
32
States / cities
Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Sep 12, 2026, 2:54 PM EDT
Completed Phase 3 Interventional Results available

Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis

NCT03667690
View directory record Official record
Conditions
Candidemia, Mycoses, Fungal Infection, Invasive Candidiases
Interventions
Rezafungin for Injection, Caspofungin, Fluconazole, intravenous placebo, oral placebo
Drug
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
19
States / cities
Birmingham, Alabama • Sacramento, California • Atlanta, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2023 · Synced Sep 12, 2026, 2:54 PM EDT
Completed No phase listed Observational

Novel Rinse to Treat in Oral Candidiasis in Cancer Patients

NCT00612963
View directory record Official record
Conditions
Candidiasis, Oral, Thrush, Candidiasis
Interventions
Frio Oral Rinse
Drug
Lead sponsor
Biomedical Development Corporation
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Kansas City, Missouri • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 7, 2010 · Synced Sep 12, 2026, 2:54 PM EDT
Completed Not applicable Interventional

Safety and Effectiveness of Giving Lamisil to HIV-Positive Subjects With Thrush Who Have Not Responded to Fluconazole Treatment

NCT00002394
View directory record Official record
Conditions
Candidiasis, Oral, HIV Infections
Interventions
Terbinafine hydrochloride
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
9
States / cities
Fort Lauderdale, Florida • Fort Myers, Florida • Tamarac, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 12, 2026, 2:54 PM EDT
Completed Not applicable Interventional

Acidophilus for the Treatment and Prevention of Oral Candidiasis in Patients Undergoing Radiation Therapy

NCT00768794
View directory record Official record
Conditions
Oral Candidiasis
Interventions
Acidophilus, Acidolphilus
Dietary Supplement
Lead sponsor
Summa Health System
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Sep 12, 2026, 2:54 PM EDT
Completed Phase 2 Interventional Results available

CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension

NCT02734862
View directory record Official record
Conditions
Candidemia, Mycoses, Fungal Infection, Fungemia, Invasive Candidiasis
Interventions
CD101, Caspofungin, Fluconazole, intravenous placebo, oral placebo
Drug
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
16
States / cities
Birmingham, Alabama • Davis, California • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Sep 12, 2026, 2:54 PM EDT
Completed Not applicable Interventional

A Study of Treatments for Fungal Infections of the Mouth and Throat in HIV-Infected Patients Who Have Had Success With Itraconazole But Not With Fluconazole

NCT00002341
View directory record Official record
Conditions
Candidiasis, Oral, HIV Infections
Interventions
Itraconazole
Drug
Lead sponsor
Janssen, LP
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 12, 2026, 2:54 PM EDT
Terminated No phase listed Observational

Incidence of Oral Candidiasis, Prevalence of C. Dubliniensis in HIV Patients and In-vitro Azole Susceptibility

NCT00692783
View directory record Official record
Conditions
Candidiasis, HIV Infections
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 7, 2015 · Synced Sep 12, 2026, 2:54 PM EDT
Completed Not applicable Interventional

Comparative Randomized Study of the Efficacy, Safety, and Toleration of Fluconazole Oral Suspension or Nystatin Oral Suspension in the Treatment of Patients With Oropharyngeal Candidiasis in Association With the Acquired Immunodeficiency Syndrome

NCT00002112
View directory record Official record
Conditions
Candidiasis, Oral, HIV Infections
Interventions
Nystatin, Fluconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
Fresno, California • San Francisco, California • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 12, 2026, 2:54 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303)

NCT03734991
View directory record Official record
Conditions
Candida Vulvovaginitis
Interventions
Ibrexafungerp, Placebo
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
12 Years and older · Female only
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2021 · Synced Sep 12, 2026, 2:54 PM EDT
Not listed Phase 1Phase 2 Interventional

CelAgace™ OraRinse Solution for Treatment of Candidiasis

NCT03250923
View directory record Official record
Conditions
Candidiasis, Oral
Interventions
silver citrate complex and acemannan
Drug
Lead sponsor
CelaCare Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced Sep 12, 2026, 2:54 PM EDT